drugset / Trial / NCT06294236
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
Non-randomizedSequentialOpen-labelTreatment
Summary
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
Timeline
- Start
- 2024-04-29
- Primary completion
- 2027-12
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SC291 | Cell therapy | — | — |